Data completeness
0/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELOSEF '250' (Cephradine) is an oral first-generation cephalosporin antibiotic in capsule form developed by Teva. It is indicated for bacterial infections susceptible to cephalosporins, working by inhibiting bacterial cell wall synthesis. This is a classic antibiotic with a long history of clinical use across multiple infection types.
Pre-Launch
Pre-launch status indicates active commercialization preparation; team building and launch planning roles are likely active.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VELOSEF '250' offers launch-phase career exposure in a competitive generic antibiotic market where commercial execution, pricing strategy, and market access are critical. Career growth may be limited by the commodity nature of the product, but launch experience in a Teva-backed initiative provides valuable go-to-market credentials.
Brand ManagerField Sales Representative
Worked on VELOSEF '250' at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.